Abstract:Background: Drug resistance is one of the biggest challenges in cancer therapy. temozolomide (TMZ) represents the most important chemotherapeutic option for glioma treatment. However, the therapeutic efficacy of TMZ remains very limited due to its frequent resistance in glioma, and the underlying mechanisms were not fully addressed. Herein, we demonstrate that the elevated expression of CD147 contributes to TMZ resistance in glioma cells, potentially through the post-translational regulation of Nrf2 expression. Methods: Cell-based assays of CD147 triggered drug resistance were performed through Edu-incorporation assay, CCK8 assay, TUNEL staining assay and flow cytometric assay. Luciferase reporter assay, protein stability related assays, co-immunoprecipitation assay were used to determine CD147 induction of Nrf2 expression through β-TrCP dependent ubiquitin system. Finally, the effect of the CD147/Nrf2 signaling on glioma progression and TMZ resistance were evaluated by functional experiments and clinical samples. Results: Based on the analysis of clinical glioma tissues, CD147 is highly expressed in glioma tissues and positively associated with tumor malignancy. Suppression of CD147 expression increased the inhibitory effect of TMZ on cell survival in both U251 and T98G cells, whereas the gain of CD147 function blocked TMZ-induced ROS production and cell death. Mechanistic study indicates that CD147 inhibited GSK3β/β-TrCP-dependent Nrf2 degradation by promoting Akt activation, and subsequently increased Nrf2-mediated anti-oxidant gene expressions. Supporting the biological significance, the reciprocal relationship between CD147 and Nrf2 was observed in glioma tissues, and associated with patient outcome. Conclusions: Our data provide the first evidence that glioma resistance to TMZ is potentially due to the activation of CD147/Nrf2 axis. CD147 promotes Nrf2 stability through the suppression of GSK3β/β-TrCP dependent Nrf2 protein degradation, which results in the ablation of TMZ induced ROS production. As such, we point out that targeting CD147/Nrf2 axis may provide a new strategy for the treatment of TMZ resistant gliomas.

TOPK inhibits autophagy by phosphorylating ULK1 and promotes glioma resistance to TMZ

T-lymphokine-activated killer cell-originated protein kinase (TOPK) as a prognostic factor and a potential therapeutic target in glioma

LRIG1 Dictates the Chemo-Sensitivity of Temozolomide (TMZ) in U251 Glioblastoma Cells Via Down-Regulation of EGFR/topoisomerase-2/Bcl-2

TTK Protein Kinase Promotes Temozolomide Resistance Through Inducing Autophagy in Glioblastoma.

AKT2-knockdown Suppressed Viability with Enhanced Apoptosis, and Attenuated Chemoresistance to Temozolomide of Human Glioblastoma Cells in Vitro and in Vivo.

Targeting Hyperactivated DNA-PKcs by KU0060648 Inhibits Glioma Progression and Enhances Temozolomide Therapy Via Suppression of AKT Signaling

Suppression of ITPKB degradation by Trim25 confers TMZ resistance in glioblastoma through ROS homeostasis

Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo

Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide.

Inhibition Of Elongation Factor-2 Kinase Augments The Antitumor Activity Of Temozolomide Against Glioma

IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma

PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma

The role of T-LAK cell-originated protein kinase in targeted cancer therapy

Kinome‐Wide Synthetic Lethal Screen Identifies PANK4 As a Modulator of Temozolomide Resistance in Glioblastoma

Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma

Suppressing TRAP1 sensitizes glioblastoma multiforme cells to temozolomide

PomGnT1 enhances temozolomide resistance by activating epithelial-mesenchymal transition signaling in glioblastoma

Leucine-rich Repeat Containing 4 Act As an Autophagy Inhibitor That Restores Sensitivity of Glioblastoma to Temozolomide

TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun.

Inhibition of mitochondria- and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells

CD147 confers temozolomide resistance of glioma cells via the regulation of β-TrCP/Nrf2 pathway